Literature DB >> 32650677

Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement.

Fateeha Furqan1, Grace Watson1, Felipe Samaniego1, Luis E Fayad1, Michael W Morrison1, Philip A Thompson2, Raphael E Steiner1, Linda Chi3, Bouthaina Dabaja4, Chelsea C Pinnix4, Sattva S Neelapu1, Loretta J Nastoupil1, Paolo Strati1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32650677      PMCID： PMC7683361          DOI： 10.1080/10428194.2020.1791849

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  15 in total

1.  Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse.

Authors:  Sophie Bernard; Lauriane Goldwirt; Sandy Amorim; Pauline Brice; Josette Brière; Eric de Kerviler; Samia Mourah; Hélène Sauvageon; Catherine Thieblemont
Journal:  Blood       Date:  2015-08-03       Impact factor: 22.113

2.  Central nervous system manifestations of marginal zone B-cell lymphoma.

Authors:  Soley Bayraktar; Alexandra Stefanovic; Naomi Montague; Janet Davis; Timothy Murray; Izidore S Lossos
Journal:  Ann Hematol       Date:  2010-05-04       Impact factor: 3.673

3.  Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia.

Authors:  Anne Wanquet; Rudy Birsen; Richard Lemal; Mathilde Hunault; Véronique Leblond; Thérèse Aurran-Schleinitz
Journal:  Blood       Date:  2016-03-18       Impact factor: 22.113

4.  Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  P Brice; Y Bastion; E Lepage; N Brousse; C Haïoun; P Moreau; N Straetmans; H Tilly; I Tabah; P Solal-Céligny
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

5.  Primary dural lymphomas: a clinicopathologic study of treatment and outcome in eight patients.

Authors:  Fabio M Iwamoto; Lisa M DeAngelis; Lauren E Abrey
Journal:  Neurology       Date:  2006-06-13       Impact factor: 9.910

6.  Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.

Authors:  Michail S Lionakis; Kieron Dunleavy; Mark Roschewski; Brigitte C Widemann; John A Butman; Roland Schmitz; Yandan Yang; Diane E Cole; Christopher Melani; Christine S Higham; Jigar V Desai; Michele Ceribelli; Lu Chen; Craig J Thomas; Richard F Little; Juan Gea-Banacloche; Sucharita Bhaumik; Maryalice Stetler-Stevenson; Stefania Pittaluga; Elaine S Jaffe; John Heiss; Nicole Lucas; Seth M Steinberg; Louis M Staudt; Wyndham H Wilson
Journal:  Cancer Cell       Date:  2017-05-25       Impact factor: 31.743

7.  Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.

Authors:  Ariela Noy; Sven de Vos; Catherine Thieblemont; Peter Martin; Christopher R Flowers; Franck Morschhauser; Graham P Collins; Shuo Ma; Morton Coleman; Shachar Peles; Stephen Smith; Jacqueline C Barrientos; Alina Smith; Brian Munneke; Isaiah Dimery; Darrin M Beaupre; Robert Chen
Journal:  Blood       Date:  2017-02-06       Impact factor: 22.113

Review 8.  Extranodal Marginal Zone Lymphoma of the Central Nervous System.

Authors:  Adanma Ayanambakkam; Sami Ibrahimi; Khalid Bilal; Mohamad A Cherry
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2017-09-23

9.  Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL).

Authors:  Therasa Kim; He Yun Choi; Hyun-Seo Lee; Sung-Hoon Jung; Jae-Sook Ahn; Hyeoung-Joon Kim; Je-Jung Lee; Hee-Doo Yoo; Deok-Hwan Yang
Journal:  BMC Cancer       Date:  2018-07-09       Impact factor: 4.430

10.  An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement.

Authors:  Andrew J Sunderland; Raphael E Steiner; Musa Al Zahrani; Chelsea C Pinnix; Bouthaina Shbib Dabaja; Jillian R Gunther; Loretta J Nastoupil; Mats Jerkeman; David Joske; Gavin Cull; Tarec El-Galaly; Diego Villa; Chan Yoon Cheah
Journal:  Cancer Med       Date:  2019-12-05       Impact factor: 4.452
View more
  1 in total

1.  Tp53 disruptions: is there a marker of poor prognosis in chronic lymphoproliferative disorders?

Authors:  Emanuele Cencini; Alberto Fabbri; Donatella Raspadori; Alessandro Gozzetti; Monica Bocchia
Journal:  Blood Res       Date:  2021-12-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.